AstraZeneca’s Tagrisso Plus Chemotherapy Receives NMPA’s Approval to Treat EGFR-Mutated Advanced Lung Cancer
Shots:
- Approval was based on P-III (FLAURA2) study of Tagrisso + CT, followed by Tagrisso with pemetrexed maintenance as a 1L treatment of patients (n=557) with locally advanced (stage IIIB-IIIC) or metastatic (stage IV) EGFRm NSCLC
- Study depicted a 38% PFS with mPFS of 25.5mos. (Tagrisso + CT) vs 16.7mos. (Tagrisso alone) during investigator evaluation; similar PFS with mPFS of 29.4mos. vs 19.9mos. was found by BICR. Favorable OS trend (41% maturity) was seen during 2nd interim analysis, further evaluation is underway
- PFS in China cohort during investigator evaluation was 44% with mPFS of 27.4mos. vs 22.3mos.; similar PFS with mPFS of 33.2mos. vs 22.0mos. & a favorable OS trend was seen by BICR
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca’s Tagrisso Plus Chemotherapy Receives Japanese Approval to Treat EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
